Drug Abuse Treatment Outcome Study--Adolescent (DATOS-A), 1993-1995: [United States]

Drug Abuse Treatment Outcome Study - Adolescent (DATOS-A) was a
multisite, prospective, community-based,
longitudinal study of adolescents entering treatment. It was designed
to evaluate the effectiveness of adolescent drug treatment by
investigating the characteristics of the adolescent population, the
structure and process of drug abuse treatment in adolescent programs,
and the relationship of these factors with outcomes. Three major types
or modalities of programs included in the study were chemical
dependency or short-term inpatient (STI), therapeutic community or
residential (RES), and outpatient drug-free (ODF). The adolescent
battery of instruments included intake, intreatment, and follow-up
questionnaires based largely on the DATOS adult study DRUG ABUSE
TREATMENT OUTCOME STUDY (DATOS), 1991-1994: [UNITED STATES] (ICPSR
2258) instrument format, with considerable tailoring to the adolescent
population. Clients entering treatment completed two comprehensive
intake interviews (Intake 1 and Intake 2), approximately one week
apart. This information is provided in Parts 1 and 2 of the data
collection. These interviews were designed to obtain baseline data on
drug use and other behaviors, such as illegal involvement, as well as
information on background and demographic characteristics, education
and training, mental health status, employment, income and
expenditures, drug and alcohol dependence, health, religiosity and
self-concept, and motivation and readiness for treatment. The one-,
three-, and six-month intreatment interviews (Parts 3, 4, and 7)
included items on treatment access, intreatment experience, and
psychological functioning, as well as questions replicated from some
of the domains in the Intake 1 and 2 questionnaires. The 12-month
post-treatment follow-up interview (Part 5) included questions
replicated from the previous interviews, and also included
post-treatment status. Part 6 includes variables for time in treatment
and interview availability indicators. The Measures Data (Part 8) were
generated by using the Diagnostic and Statistical Manual of Mental
Disorders (Rev. 3rd ed., DSM-III-R) (American Psychiatric Association,
1987). The variables in Part 8 give either the DSM-III-R level of
dependence to a drug category or they describe whether the subject
meets the DSM-III-R standard for a particular disorder. The 12-Month
Follow-up Urine Result data (Part 9) provide the results from urine
sample tests that were given to a sample of subjects at the time of
the 12-Month Follow-up Interview. The urine test was used to ascertain
the nature and extent of bias in the self-reports of the
respondents. Urine specimens were tested for eight categories of drugs
(amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine
metabolite, methaqualone, opiates, and phencyclidine). The drugs
covered in the study were alcohol, tobacco, marijuana (hashish, THC),
cocaine (including crack), heroin, narcotics or opiates such as
morphine, codeine, Demerol, Dilaudid, and Talwin, illegal methadone,
sedatives and tranquilizers such as barbiturates and depressants,
amphetamines or other stimulants such as speed or diet pills,
methamphetamines, LSD, PCP, and other hallucinogens or psychedelics,
and inhalants such as glue, gasoline, paint thinner, and aerosol
sprays. The study also included drug of choice, frequency, and route
of administration.